Conference Coverage

Clinical advances drive lung cancer staging, classification changes


 

AT THE IASLC WORLD CONFERENCE

References

The proposed revision would continue to group in the M1a category cases with pleural/pericardial effusions, contralateral/bilateral lung nodules, contralateral/bilateral pleural nodules, or a combination of multiple parameters. However, single metastatic lesions in a single distant organ would be reclassified as M1b, and multiple lesions in a single organ or multiple lesions in multiple organs would be reclassified as M1c.

Pages

Recommended Reading

Adjuvant erlotinib showed no benefit in NSCLC patients
MDedge Hematology and Oncology
David Henry's JCSO podcast, July 2015
MDedge Hematology and Oncology
Nivolumab continues to offer better survival for squamous NSCLC patients
MDedge Hematology and Oncology
Hunger hormone mimic anamorelin treats cachexia in NSCLC
MDedge Hematology and Oncology
IASLC issues new tobacco declaration
MDedge Hematology and Oncology
Share of lung cancer patients who never smoked is rising
MDedge Hematology and Oncology
Chemotherapy plus cetuximab shows OS benefit in squamous NSCLC
MDedge Hematology and Oncology
Nivolumab benefits heavily pretreated squamous NSCLC patients
MDedge Hematology and Oncology
New cancer cases to reach nearly 2.4 million in 2035 – AACR
MDedge Hematology and Oncology
Workshop tackles finer points of lung cancer screening
MDedge Hematology and Oncology